Yonca Kanber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yonca Kanber has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Manon Auger
Department of Pathology McGill University Health Center McGill University Montreal QC Canada
2 shared publicationsMichele Charbonneau
2 shared publications- Manon Auger
Department of Pathology McGill University Montreal Quebec Canada
1 shared publication Marc Pusztaszeri
Department of Pathology Jewish General Hospital McGill University Montréal QC Canada
1 shared publication
Latest Publications
- 25 May 2021
- Published by Wiley in Cytopathology
- Vol. 32 (5) , 562-587
Immunocytochemistry for diagnostic cytopathology—A practical guide
Cytological specimens, which are obtained by minimally invasive methods, are an excellent source of diagnostic material. Sometimes they are the only material available for diagnosis as well as for prognostic/predictive markers. When cytomorphology is not straightforward, ancillary tests may be required for a definitive diagnosis to guide clinical management. Immunocytochemistry (ICC) is the most common and practical ancillary tool used to reach a diagnosis when cytomorphology is equivocal, to differentiate entities with overlapping morphological features, and to determine the cell lineage and the site of origin of a metastatic neoplasm. Numerous immunomarkers are available, and some are expressed in multiple neoplasms. To rule out entities within a differential diagnosis, the use of more than one marker, sometimes panels, is necessary. ICC panels for diagnostic purposes should be customised based on the clinical context and cytomorphology, and the markers should be used judiciously to preserve material for additional tests for targeted therapies in the appropriate setting. This review offers a practical guide for the use of ICC for diagnostic cytopathology, covering the most commonly encountered non‐hematolymphoid diagnostic scenarios in various body sites.
- 25 May 2021
- Published by Wiley in Cytopathology
- Vol. 32 (5) , 562-587
Immunocytochemistry for diagnostic cytopathology—A practical guide
Cytological specimens, which are obtained by minimally invasive methods, are an excellent source of diagnostic material. Sometimes they are the only material available for diagnosis as well as for prognostic/predictive markers. When cytomorphology is not straightforward, ancillary tests may be required for a definitive diagnosis to guide clinical management. Immunocytochemistry (ICC) is the most common and practical ancillary tool used to reach a diagnosis when cytomorphology is equivocal, to differentiate entities with overlapping morphological features, and to determine the cell lineage and the site of origin of a metastatic neoplasm. Numerous immunomarkers are available, and some are expressed in multiple neoplasms. To rule out entities within a differential diagnosis, the use of more than one marker, sometimes panels, is necessary. ICC panels for diagnostic purposes should be customised based on the clinical context and cytomorphology, and the markers should be used judiciously to preserve material for additional tests for targeted therapies in the appropriate setting. This review offers a practical guide for the use of ICC for diagnostic cytopathology, covering the most commonly encountered non‐hematolymphoid diagnostic scenarios in various body sites.
- 1 November 2015
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 4 (6) , S39
Reporting of Benign Endometrial Cells in Pap Smears
- 1 November 2015
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 4 (6) , S39
Reporting of Benign Endometrial Cells in Pap Smears
- 8 September 2015
- Published by Wiley in Cancer Cytopathology
- Vol. 123 (12) , 739-744
Pap smears with glandular cell abnormalities: Are they detected by rapid prescreening?
BACKGROUND: Rapid prescreening (RPS) is one of the quality assurance (QA) methods used in gynecologic cytology. The efficacy of RPS has been previously studied but mostly with respect to squamous lesions; in fact, there has been no study so far specifically looking at the sensitivity of RPS for detecting glandular cell abnormalities.METHODS: A total of 80,565 Papanicolaou (Pap) smears underwent RPS during a 25‐month period. A sample was designated as “review for abnormality” (R) if any abnormal cells (at the threshold of atypical squamous cells of undetermined significance/atypical glandular cells [AGC]) were thought to be present or was designated as negative (N) if none were detected. Each sample then underwent full screening (FS) and was designated as either R or N and also given a cytologic interpretation.RESULTS: The final cytologic interpretation was a glandular cell abnormality (≥AGC) in 107 samples (0.13%); 39 of these (36.4%) were flagged as R on RPS. Twenty‐four patients (33.8%) out of 71 who had histologic follow‐up were found to harbor a high‐grade squamous intraepithelial lesion or carcinoma; 13 of those 24 Pap smears (54.2%) had been flagged as R on RPS. Notably, 11 AGC cases were picked up by RPS only and not by FS and represented false‐negative cases; 2 of these showed endometrial adenocarcinoma on histologic follow‐up.CONCLUSIONS: Pap smears with glandular cell abnormalities are often flagged as abnormal by RPS, and this results in a sensitivity of 36.4% (at the AGC threshold). Most importantly, some cases of AGC are detected on Pap smears by RPS only, and this demonstrates that RPS is a valuable QA method. Cancer (Cancer Cytopathol) 2015;123:739–744. © 2015 American Cancer Society.
- 8 September 2015
- Published by Wiley in Cancer Cytopathology
- Vol. 123 (12) , 739-744
Pap smears with glandular cell abnormalities: Are they detected by rapid prescreening?
BACKGROUND: Rapid prescreening (RPS) is one of the quality assurance (QA) methods used in gynecologic cytology. The efficacy of RPS has been previously studied but mostly with respect to squamous lesions; in fact, there has been no study so far specifically looking at the sensitivity of RPS for detecting glandular cell abnormalities.METHODS: A total of 80,565 Papanicolaou (Pap) smears underwent RPS during a 25‐month period. A sample was designated as “review for abnormality” (R) if any abnormal cells (at the threshold of atypical squamous cells of undetermined significance/atypical glandular cells [AGC]) were thought to be present or was designated as negative (N) if none were detected. Each sample then underwent full screening (FS) and was designated as either R or N and also given a cytologic interpretation.RESULTS: The final cytologic interpretation was a glandular cell abnormality (≥AGC) in 107 samples (0.13%); 39 of these (36.4%) were flagged as R on RPS. Twenty‐four patients (33.8%) out of 71 who had histologic follow‐up were found to harbor a high‐grade squamous intraepithelial lesion or carcinoma; 13 of those 24 Pap smears (54.2%) had been flagged as R on RPS. Notably, 11 AGC cases were picked up by RPS only and not by FS and represented false‐negative cases; 2 of these showed endometrial adenocarcinoma on histologic follow‐up.CONCLUSIONS: Pap smears with glandular cell abnormalities are often flagged as abnormal by RPS, and this results in a sensitivity of 36.4% (at the AGC threshold). Most importantly, some cases of AGC are detected on Pap smears by RPS only, and this demonstrates that RPS is a valuable QA method. Cancer (Cancer Cytopathol) 2015;123:739–744. © 2015 American Cancer Society.